UK markets close in 4 hours 19 minutes

Centessa Pharmaceuticals plc (CNTA)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
8.72-0.15 (-1.69%)
At close: 04:00PM EDT
8.72 0.00 (0.00%)
After hours: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close8.87
Open8.87
Bid8.69 x 100
Ask8.79 x 100
Day's range8.70 - 9.06
52-week range3.96 - 12.45
Volume64,395
Avg. volume207,001
Market cap985.744M
Beta (5Y monthly)1.45
PE ratio (TTM)N/A
EPS (TTM)-1.57
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est13.60
  • Globe Newswire

    Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024

    Hemophilia Program: Ongoing registrational PRESent-2 and PRESent-3 studies of SerpinPC for the treatment of hemophilia B; PRESent-2 interim analysis planned in 2024Orexin Agonist Program: Cleared IND and initiated Phase 1 first-in-human clinical trial of ORX750, a highly potent and selective OX2R agonist for the treatment of narcolepsy; Clinical proof-of-concept data in acutely sleep-deprived healthy volunteers planned in 2H of 2024LockBody® Technology Platform: Ongoing Phase 1/2a study of LB101

  • Globe Newswire

    Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary Shares

    BOSTON and LONDON, April 23, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced the pricing of an underwritten public offering of 10,810,810 American Depositary Shares (“ADSs”), each representing one ordinary share, at a price to the public of $9.25 per ADS. The aggregate gross proceeds to Centessa from this offering are expected to be app

  • Globe Newswire

    Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares

    BOSTON and LONDON, April 23, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that it has commenced an underwritten public offering of $100 million of American Depositary Shares (“ADSs”), each representing one ordinary share. All of the ADSs are being offered by Centessa. In addition, Centessa intends to grant the underwriters a 30-day o